This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy (EXCESS)

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified November 2015 by Universitätsklinikum Hamburg-Eppendorf
CytoSorbents, Inc
Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf Identifier:
First received: October 1, 2015
Last updated: November 30, 2015
Last verified: November 2015
This study evaluates the effect of extracorporeal removal of inflammatory mediators on the systemic inflammation reaction of patients admitted to the intensive care unit following elective esophagectomy. Half of the participants will be treated with an adsorption device (CytoSorbents Adsorber), while the other half will be treated according to standard care. Significant reductions of interleukin-6 plasma concentration, SOFA score and catecholamine dosage in the intervention group are expected.

Condition Intervention Phase
Inflammation Device: CytoSorb cytokine elimination Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy - a Randomized Study (EXCESS)

Further study details as provided by Universitätsklinikum Hamburg-Eppendorf:

Primary Outcome Measures:
  • Change of interleukin-6 plasma levels [ Time Frame: 72 hours ]

Secondary Outcome Measures:
  • Change in SOFA Score [ Time Frame: 120 hours ]
    decrease of >= 2 score points in the intervention group

  • Change of catecholamine dose [ Time Frame: 48 hours ]
    decrease of >= 0.1 µg/kg/min catecholamine dosage to achieve MAP > 65 mmHg in intervention group

  • Fluid intake [ Time Frame: 120 hours ]
    reduction of fluid intake to maintain MAP > 65 mmHg of >= 1000 ml/24h in intervention group

Estimated Enrollment: 24
Study Start Date: December 2015
Estimated Study Completion Date: September 2016
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Standard Care
intensive care therapy according to international standards and following local SOPs, including fluid therapy, mechanical ventilation, catecholamine therapy and other pharmacotherapy as required
Experimental: CytoSorb
all of the above, plus extracorporeal hemadsorption therapy (CytoSorbents Adsorber cartridge) using continuous veno-venous hemofiltration (citrate anticoagulation) CytoSorb cytokine elimination
Device: CytoSorb cytokine elimination
Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
Other Name: hemadsorption

Detailed Description:

Radical esophagectomy combined with extensive lymphadenectomy for esophageal cancer is one of the most invasive surgical procedures. Even with progress made in surgical technique and postoperative management the rate of short- and long term complications remains high. The surgical trauma invariably causes liberation and activation of inflammatory mediators and danger associated molecular patterns, which in turn result in a pronounced systemic inflammatory reaction, leading to multiorgan dysfunction including adult respiratory distress syndrome (ARDS) in many patients. The subsequent counter regulation of the immune system induces immune paralysis, which is followed by infectious complications and increases the probability of severe sepsis. Moreover, severe systemic inflammation causes capillary leakage, resulting in impaired wound healing and endangered anastomoses.

Therefore, it seems that early and effective measures against the excessive production of mediators and cytokines are indicated without impairment of the innate and adaptive immune response as it would be expected with the administration of e.g. steroids. Instead, the removal of an excessive amount of circulating cytokines might be a desirable method having shown its effectivity in the therapy of septic shock in the past.

The aim of this study is to demonstrate the effectiveness of extracorporeal cytokine removal to dampen the systemic inflammatory response following abdominal-thoracic esophagectomy.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • abdominal-thoracic esophagectomy with radical lymphadenectomy
  • post operative admission to ICU
  • age >= 18 yrs
  • written informed consent

Exclusion Criteria:

  • Participation in another interventional trial
  • pregnancy or lactation
  • systemic medication with high dose steroids and/or immunosuppressants and/or radiotherapy during the last 3 months
  • known diseases of the immune system (benign and malign)
  • contraindications for extracorporeal therapy
  • Thrombocytopenia < 50*10^9/l
  • therapy limitations (DNR), moribund status
  • missing informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02606799

Contact: Stefan Kluge, MD +49 40 7410 57010
Contact: Axel Nierhaus, MD +49 40 7410 55325

University Medical Center Hamburg-Eppendorf Not yet recruiting
Hamburg, Germany, 20251
Contact: Stefan Kluge, MD    +49 40 7410 57010   
Contact: Axel Nierhaus, MD    +49 40 7410 55325   
Principal Investigator: Axel Nierhaus, MD         
Sponsors and Collaborators
Universitätsklinikum Hamburg-Eppendorf
CytoSorbents, Inc
Principal Investigator: Axel Nierhaus, MD University Medical Center Hamburg-Eppendorf, Dep. of Critical Care
  More Information

Additional Information:
Responsible Party: Universitätsklinikum Hamburg-Eppendorf Identifier: NCT02606799     History of Changes
Other Study ID Numbers: KIM_CS_001
Study First Received: October 1, 2015
Last Updated: November 30, 2015

Keywords provided by Universitätsklinikum Hamburg-Eppendorf:
Esophagectomy Inflammation Hemoperfusion Cytokines

Additional relevant MeSH terms:
Pathologic Processes processed this record on September 21, 2017